MedTrace Logo

Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19

NCT05620160 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1359

Last updated 2023-05-24

No results posted yet for this study

Summary

This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of RAY1216 tablets in the treatment of mild to moderate SARS-CoV-2 infection. The total study duration is up to 28 days.

Conditions

  • Mild to Moderate COVID-19

Interventions

DRUG

RAY1216

RAY1216（tablet）

DRUG

Placebo

placebo （tablet）

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-12
Primary Completion
2023-01-19
Completion
2023-03-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05620160 on ClinicalTrials.gov